# Occupational and environmental lung diseases

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/occupational-and-environmental-lung-diseases/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the research related to malignant pleural mesothelioma, with a particular emphasis on topics such as BAP1 mutations, asbestos exposure, immunotherapy, occupational carcinogens, genetic predisposition, radiation therapy, tumor suppressor genes, pleurectomy/decortication, and diagnostic markers. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11026 |
| Works | 169 |

## Topic papers all

Showing 15 of 169.

- [Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015](https://scholariq.org/papers/global-regional-and-national-comparative-risk-assessment-of-79-behavioural/)
- [Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016](https://scholariq.org/papers/global-regional-and-national-comparative-risk-assessment-of-84-behavioural-2/)
- [Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE)](https://scholariq.org/papers/air-pollution-and-lung-cancer-incidence-in-17-european-cohorts-prospective/)
- [First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural/)
- [Statistical software for analyzing the health effects of multiple concurrent exposures via Bayesian kernel machine regression](https://scholariq.org/papers/statistical-software-for-analyzing-the-health-effects-of-multiple-concurrent/)
- [Outdoor Particulate Matter Exposure and Lung Cancer: A Systematic Review and Meta-Analysis](https://scholariq.org/papers/outdoor-particulate-matter-exposure-and-lung-cancer-a-systematic-review-and-meta/)
- [Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-for-newly-diagnosed-pleural-mesothelioma-in-the-mesothelioma-avastin/)
- [Lung Cancer Risk after Exposure to Polycyclic Aromatic Hydrocarbons: A Review and Meta-Analysis](https://scholariq.org/papers/lung-cancer-risk-after-exposure-to-polycyclic-aromatic-hydrocarbons-a-review-and/)
- [Integrative Molecular Characterization of Malignant Pleural Mesothelioma](https://scholariq.org/papers/integrative-molecular-characterization-of-malignant-pleural-mesothelioma/)
- [Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion](https://scholariq.org/papers/binding-of-ovarian-cancer-antigen-ca125-muc16-to-mesothelin-mediates-cell/)
- [A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab](https://scholariq.org/papers/a-phase-i-trial-of-regional-mesothelin-targeted-car-t-cell-therapy-in-patients/)
- [Deep learning-based classification of mesothelioma improves prediction of patient outcome](https://scholariq.org/papers/deep-learning-based-classification-of-mesothelioma-improves-prediction-of/)
- [Inhaled carbon nanotubes reach the subpleural tissue in mice](https://scholariq.org/papers/inhaled-carbon-nanotubes-reach-the-subpleural-tissue-in-mice/)
- [Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial](https://scholariq.org/papers/nivolumab-or-nivolumab-plus-ipilimumab-in-patients-with-relapsed-malignant/)
- [Mesothelioma: Scientific clues for prevention, diagnosis, and therapy](https://scholariq.org/papers/mesothelioma-scientific-clues-for-prevention-diagnosis-and-therapy/)

## Topic primary papers

Showing 15 of 75.

- [First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural/)
- [Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-for-newly-diagnosed-pleural-mesothelioma-in-the-mesothelioma-avastin/)
- [Integrative Molecular Characterization of Malignant Pleural Mesothelioma](https://scholariq.org/papers/integrative-molecular-characterization-of-malignant-pleural-mesothelioma/)
- [Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion](https://scholariq.org/papers/binding-of-ovarian-cancer-antigen-ca125-muc16-to-mesothelin-mediates-cell/)
- [Deep learning-based classification of mesothelioma improves prediction of patient outcome](https://scholariq.org/papers/deep-learning-based-classification-of-mesothelioma-improves-prediction-of/)
- [Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial](https://scholariq.org/papers/nivolumab-or-nivolumab-plus-ipilimumab-in-patients-with-relapsed-malignant/)
- [Mesothelioma: Scientific clues for prevention, diagnosis, and therapy](https://scholariq.org/papers/mesothelioma-scientific-clues-for-prevention-diagnosis-and-therapy/)
- [Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline](https://scholariq.org/papers/treatment-of-malignant-pleural-mesothelioma-american-society-of-clinical/)
- [Diseases caused by silica: mechanisms of injury and disease development](https://scholariq.org/papers/diseases-caused-by-silica-mechanisms-of-injury-and-disease-development/)
- [Mesothelin Immunotherapy for Cancer: Ready for Prime Time?](https://scholariq.org/papers/mesothelin-immunotherapy-for-cancer-ready-for-prime-time/)
- [BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations](https://scholariq.org/papers/bap1-brca1-associated-protein-1-is-a-highly-specific-marker-for-differentiating/)
- [First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-versus-chemotherapy-in-patients-with/)
- [Occupation and cancer in Britain](https://scholariq.org/papers/occupation-and-cancer-in-britain/)
- [Occupational cancer burden in Great Britain](https://scholariq.org/papers/occupational-cancer-burden-in-great-britain/)
- [Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and <i>P16/CDKN2A</i> Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction](https://scholariq.org/papers/global-gene-expression-profiling-of-pleural-mesotheliomas-overexpression-of/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.